From allosteric mechanisms to selective medicines
Advancing programs in neurodegeneration and expanding into therapeutic areas including oncology and pain. We focus on targets where dynamic regulation and selectivity create opportunities for differentiated therapeutic intervention.
Advancing focused therapeutic programs
AllotarX™ accelerates the identification and refinement of therapeutic candidates by integrating physics-based, AI-driven approaches with closed-loop learning.
High-Impact Targets
We focus on targets governed by dynamic regulatory mechanisms, where traditional structure-based approaches have struggled and allosteric control can create new intervention opportunities.
New Interventions
Working from conformational ensembles, we uncover allosteric mechanisms, including transient regulatory sites and states, that static structural models do not reveal.
Selective Candidates
We design and optimize selective modulators, refining candidates against related proteins through experimental feedback and closed-loop learning.
Our programs
Each program advances from Site & Selectivity Design through Hit Discovery & Validation and Lead Optimization to Development Candidate.
Alzheimer’s disease
Selective allosteric modulation of APH1B-containing γ‑secretase to reshape amyloid-β processing.
NIH SBIR Phase IGLP-1 receptor (neurodegeneration)
CNS-targeted allosteric modulation of GLP-1R to enhance endogenous receptor signaling.
InternalAsset-centric strategy
Programs are advanced toward value-creating milestones and strategic partnering opportunities.
Partnership potential
Program design supports future co-development, licensing, and pharma collaboration pathways.
Expansion
Beyond our lead programs, we are running early-stage discovery on additional targets in rare diseases, with oncology and pain as future growth areas.

